Credit Suisse Ag Kura Oncology, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 72,494 shares of KURA stock, worth $782,935. This represents 0.0% of its overall portfolio holdings.

Number of Shares

72,494

Previous 69,202 4.76%

Holding current value

$782,935

Previous $995,000 55.38%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$13.42 - $23.53 $44,178 - $77,460	3,292 Added 4.76%	72,494 $1.55 Million
Q4 2023 Feb 08, 2024	SELL	$7.58 - $14.38 $20,390 - $38,682	-2,690 Reduced 3.74%	69,202 $995,000
Q3 2023 Nov 13, 2023	SELL	$8.44 - $11.86 $65,139 - $91,535	-7,718 Reduced 9.69%	71,892 $655,000
Q2 2023 Aug 11, 2023	BUY	$9.62 - $13.99 $74,131 - $107,806	7,706 Added 10.72%	79,610 $842,000
Q1 2023 May 10, 2023	BUY	$10.71 - $14.6 $73,427 - $100,097	6,856 Added 10.54%	71,904 $879,000
Q4 2022 Feb 13, 2023	BUY	$11.23 - $16.9 $138,005 - $207,684	12,289 Added 23.29%	65,048 $807,000
Q3 2022 Nov 10, 2022	BUY	$12.01 - $19.45 $67,988 - $110,106	5,661 Added 12.02%	52,759 $721,000
Q2 2022 Aug 12, 2022	SELL	$10.71 - $18.33 $38,041 - $65,108	-3,552 Reduced 7.01%	47,098 $863,000
Q1 2022 May 16, 2022	BUY	$11.78 - $16.98 $14,925 - $21,513	1,267 Added 2.57%	50,650 $815,000
Q4 2021 Feb 14, 2022	BUY	$12.22 - $19.57 $72,562 - $116,206	5,938 Added 13.67%	49,383 $692,000
Q3 2021 Nov 12, 2021	SELL	$15.42 - $21.72 $220,228 - $310,205	-14,282 Reduced 24.74%	43,445 $814,000
Q2 2021 Aug 16, 2021	BUY	$20.85 - $29.88 $325,781 - $466,875	15,625 Added 37.11%	57,727 $1.2 Million
Q1 2021 May 14, 2021	SELL	$24.75 - $39.14 $14.9 Million - $23.5 Million	-601,022 Reduced 93.45%	42,102 $1.19 Million
Q4 2020 Feb 12, 2021	BUY	$29.0 - $41.62 $944,646 - $1.36 Million	32,574 Added 5.34%	643,124 $21 Million
Q3 2020 Nov 13, 2020	BUY	$16.3 - $30.64 $8.93 Million - $16.8 Million	547,762 Added 872.4%	610,550 $18.7 Million
Q2 2020 Aug 12, 2020	BUY	$7.95 - $18.81 $374,119 - $885,179	47,059 Added 299.19%	62,788 $1.02 Million
Q1 2020 May 13, 2020	SELL	$6.45 - $14.04 $175,975 - $383,053	-27,283 Reduced 63.43%	15,729 $157,000
Q4 2019 Feb 12, 2020	BUY	$12.97 - $15.94 $266,650 - $327,710	20,559 Added 91.56%	43,012 $591,000
Q3 2019 Nov 12, 2019	BUY	$14.75 - $20.87 $49,722 - $70,352	3,371 Added 17.67%	22,453 $341,000
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $69,593 - $93,626	4,731 Added 32.97%	19,082 $375,000
Q1 2019 May 14, 2019	BUY	$13.73 - $16.87 $20,842 - $25,608	1,518 Added 11.83%	14,351 $238,000
Q4 2018 Feb 13, 2019	SELL	$10.6 - $17.49 $56,275 - $92,854	-5,309 Reduced 29.26%	12,833 $180,000
Q3 2018 Nov 13, 2018	BUY	$16.65 - $21.85 $81,068 - $106,387	4,869 Added 36.68%	18,142 $318,000
Q2 2018 Aug 14, 2018	BUY	$14.8 - $18.8 $196,440 - $249,532	13,273 New	13,273 $241,000
Q4 2017 Feb 14, 2018	SELL	$13.5 - $16.65 $172,273 - $212,470	-12,761 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$6.05 - $14.95 $77,204 - $190,776	12,761	12,761 $190,000

Others Institutions Holding KURA

# of Institutions

185

Shares Held

81.8M

Call Options Held

42.1K

Put Options Held

34K

View Full List

About Kura Oncology, Inc.

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $722M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

More about KURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account